Atlas Trials

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Clinical trial NCT06172127 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06172127
Sponsor
MedSIR
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2024-07-22
Primary completion
2027-04-01
Enrollment
165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.